New Report Examines Biotech Giant Amgen’s Success and Future Direction
Amgen is the world’s largest biotechnology company and the eighth largest pharmaceutical company worldwide, with revenues reaching $10 billion in 2004. Arrowhead Publishers’ new report takes a detailed look at the company’s many successes and its strategy for the future. (http://www.arrowheadpublishers.com/Amgen.html)
Minneapolis, MN (PRWEB) July 26, 2005 -- Amgen is the world’s largest
biotechnology company and the eighth largest pharmaceutical company worldwide.
Revenues have nearly doubled in the last three years, going from $5.52 billion
in 2002 to $10.55 billion in 2004. Yet the majority of revenue is based on
twenty-year old technology. Can Amgen continue its amazing revenue growth? Or
will it fall behind, lacking the small molecule therapeutics that are the main
stay of modern pharmaceuticals?
Arrowhead Publishers’ new report entitled
"Amgen: Profile, Patents and Pipeline" answers these important questions. It
provides detailed analysis and information concerning Amgen's business
activities. This report also includes a thorough accounting of the company’s
patents and patent applications.
This report provides an in-depth
analysis of Amgen’s
• Strategic strengths and
weaknesses
• Current therapeutic products and pipeline of
future products
• Financial analysis, including R&D
productivity
• Current patents and patent
applications
• Alliances, joint ventures and
acquisitions
• Key personnel
Who should buy this
report?
• Biotech and pharmaceutical companies of all
sizes interested in understanding Amgen’s rapid climb to success and its future
direction
• Early stage biotechnology companies interested
in understanding Amgen Ventures strategy for investing its $100 million
• Financial analysts looking for an in-depth technical
analysis of Amgen’s future revenue sources
Key reasons to purchase this
report
• Competitive
intelligence
• Benchmark company performance against the
leading biotechnology company
• Understand what is driving
Amgen's growth, and what is holding it back
This 81 page up-to-date
report, based on information gathered through the end of the first quarter 2005,
contains five tables on Amgen’s pipeline; a listing of the last three years of
granted patents, analyzed by therapeutic area as well as therapeutic form; a
breakdown of sales for all key products; both U.S. and International, as well as
a list of all patent applications for 2004 through the first quarter of
2005.
# # #
Source : http://www.prweb.com/releases/2005/7/prweb264769.htm